Despite ban, Martin Shkreli can’t seem to kick the pharma habit
pharmaphorum
JULY 26, 2022
” That is certainly a departure from Shkreli’s earlier efforts to disrupt the healthcare category by inflating the price of critical HIV medication Daraprim by around 5,000% when he was chief executive at Turing Pharma.
Let's personalize your content